Nexavar Blog
Join the 'Nexavar' group to help and get support from people like you.
Scientists Learn How Cancer Drugs Cause Hypertension
Posted 8 weeks ago by Drugs.com
WEDNESDAY, Aug. 5 – A new study reveals why high blood pressure develops in up to one-third of cancer patients who take drugs to block the formation of blood vessels that feed tumors.
"Anti-angiogenesis drugs like Avastin, Sutent or Nexavar inhibit an important substance called vascular endothelial growth factor [VEGF] that stimulates the creation of new vessels that support malignant growth," senior study author Dr. Thomas Coffman, a professor of medicine, cell biology and immunology at Duke University Medical Center in Durham, N.C., said in a school news release. "Our studies in mice show that blocking VEGF causes hypertension because it disrupts an important biological system – the nitric oxide pathway that regulates blood vessel health." Read more...
New Drugs, New Combinations Fight Breast Cancer
Posted 8 weeks ago by Drugs.com
FRIDAY, Dec. 11 – New therapies and new spins on existing treatments are offering hope for patients with breast cancer, especially those with metastatic disease, according to research being presented this week at the annual San Antonio Breast Cancer Symposium in San Antonio, Texas.
One study found that a higher (500-milligram) dose of Faslodex (fulvestrant) works better than the currently approved 250-milligram dose in hormone receptor-positive breast tumors that had already spread to other parts of the body. There was no difference in the severity of side effects between the two doses, researchers added. Read more...
Related support groups: Faslodex, Femara, Nexavar, Breast Cancer, Breast Cancer, Metastatic
Drug Helps Asians Battling Liver Cancer
Posted 3+ months ago by Drugs.com
TUESDAY, Dec. 16 – The drug sorafenib increased overall survival in Asian-Pacific patients with advanced liver cancer, according to the results of a study that included 226 patients in China, South Korea and Taiwan.
The 150 patients in the treatment group received 400 milligrams of sorafenib (Nexavar) twice a day in six-week cycles, while those in the control group received a placebo.
Median overall survival was 6.5 months for those in the treatment group and 4.2 months for those in the control group. The study also found that sorafenib prolonged the time to progression and disease control rate. Read more...
Related support groups: Nexavar
Drug Sorafenib Improves Kidney Cancer Outcomes
Posted 3+ months ago by Drugs.com
THURSDAY, Oct. 9 – People with kidney cancer, regardless of age, seem to benefit from and tolerate sorafenib drug therapy equally well, a new study says.
The finding, published online Oct. 7 in the Journal of the National Cancer Institute, counters the general perception that older patients derive less benefit from the therapy and are more likely to suffer side effects than younger patients.
The study, conducted by Tim Eisen of Addenbrooke's Hospital and the University of Cambridge in the United Kingdom and colleagues, found patients age 70 and older and those 69 and younger had similar responses to the drug in terms of self-reported health deterioration and improved quality of life over that time. Read more...
Related support groups: Nexavar
Drug Re-Sensitizes Breast Tumors to Treatment
Posted 3+ months ago by Drugs.com
FRIDAY, Sept. 5 – The drug sorafenib may help "re-sensitize" certain breast cancer tumors to anti-hormonal drugs, Georgetown University Medical Center researchers say.
Women with estrogen-receptor or progesterone-receptor positive (ER or PR positive) metastatic breast cancers often take anti-hormonal medicines, such as aromatase inhibitors, to keep the cancer under control. Aromatase inhibitors lower the amount of estrogen in the body.
However, the tumor eventually becomes resistant to anti-hormonal drugs, and the cancer begins to grow. Read more...
Related support groups: Nexavar, Breast Cancer
Ask a Question
You may also be interested in...
Related Condition Support Groups
Hepatocellular Carcinoma, Thyroid Cancer, Renal Cell Carcinoma, Hepatic Tumor
